Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries

Young Joon Hong, Myung Ho Jeong, Weon Kim, Sang Yup Lim, Sang Hyun Lee, Seo Na Hong, Ju Han Kim, Young Keun Ahn, Jeong Gwan Cho, Jong Chun Park, Dong Lyun Cho, Hoon Kim, Jung Chaee Kang

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)

Abstract

The investigators tested whether abciximab-coated stents prevent neointimal hyperplasia (NIH) formation in coronary de novo lesions. Abciximab-coated stents were compared with control stents. All patients underwent follow-up coronary angiography and intravascular ultrasound (IVUS). All stents were successfully deployed, and patients were discharged home without clinical events. At follow-up coronary angiography, the restenosis rate and late loss were 14% and 0.33 ± 0.28 mm in the abciximab-coated stent group and 28.6% and 0.64 ± 0.32 mm in the control stent group (p = 0.099 and p = 0.014, respectively). At follow-up IVUS, the intrastent luminal area and intrastent NIH area were 5.7 ± 1.6 and 2.0 ± 1.6 mm 2, respectively, in the abciximab-coated stent group and 4.2 ± 0.8 and 3.4 ± 1.7 mm 2, respectively, in the control stent group (p = 0.001 and p = 0.001, respectively). Abciximab-coated stents are feasible and significantly inhibit NIH, with potential therapeutic benefit in preventing stent restenosis.

Original languageEnglish
Pages (from-to)1050-1054
Number of pages5
JournalAmerican Journal of Cardiology
Volume94
Issue number8
DOIs
Publication statusPublished - 2004 Oct 15
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries'. Together they form a unique fingerprint.

Cite this